Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
about
Survivin: a unique target for tumor therapyThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.Using lymph node swelling as a potential biomarker for successful vaccination.Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.The twisted survivin connection to angiogenesisMechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.Current and emerging treatment options in the management of advanced ovarian cancer.Translational nanoparticle engineering for cancer vaccines.Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine.Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control.Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination.A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo.A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.Trial watch: Immunogenic cell death induction by anticancer chemotherapeuticsEarly Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal MetastasisNext Generation Cancer Vaccines-Make It Personal!
P2860
Q26747332-E3B959C2-FBAA-480D-AF10-AAE8936FABBBQ33815087-06946CE2-8E34-4843-870F-3D289D453A4DQ33853324-6074792B-8D33-4272-B6EF-F3CEE4F4D507Q36032562-2B44F479-A9E3-45AA-A3BB-3628B33C8B66Q36173622-60472778-3021-4E9B-9957-053F421D5013Q36301932-469A1C9E-1B0D-44BB-AA45-C80161260046Q37733068-84F5E460-5652-4D50-A96F-8FDE7BC0ED23Q38751236-829209BA-8389-4DD3-9595-6221A2C36C44Q46720677-0613B9D4-04FA-4F58-8062-859AECD05A40Q47296148-459B54F2-ED48-4695-85E5-05F34DAB0650Q47699178-0C8F749A-E71C-4003-9744-15199D02028DQ48316344-5A7CB98D-8050-4DAD-BB8E-1FB5A9A8C151Q49496705-2C82A430-284D-4605-9731-B1742D11C09AQ52607180-6F9F1909-D490-4230-B9F8-30C56DE0A687Q52655499-A2FEAA87-7C60-4660-961D-0C0DD32CA540Q52822549-4D320AEB-316C-4091-8E9A-98BD235534B1Q56594845-B637D64D-4291-48A4-A83D-464FCE9326DFQ58788761-69650B1C-B684-44E9-8A0D-42C14CFDB9A5Q58791982-4F911945-232F-4A60-9A39-81488FC5415A
P2860
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Survivin-targeted immunotherap ...... anced ovarian cancer patients.
@ast
Survivin-targeted immunotherap ...... anced ovarian cancer patients.
@en
type
label
Survivin-targeted immunotherap ...... anced ovarian cancer patients.
@ast
Survivin-targeted immunotherap ...... anced ovarian cancer patients.
@en
prefLabel
Survivin-targeted immunotherap ...... anced ovarian cancer patients.
@ast
Survivin-targeted immunotherap ...... anced ovarian cancer patients.
@en
P2093
P2860
P50
P1433
P1476
Survivin-targeted immunotherap ...... anced ovarian cancer patients.
@en
P2093
Amit M Oza
Andrea Penwell
Genevieve M Weir
James Bentley
Jeannine A Villella
John J Nemunaitis
Kendall Sharp
Leeladhar Sammatur
Lisa D MacDonald
Marc Mansour
P2860
P304
P356
10.1080/2162402X.2015.1026529
P577
2015-05-07T00:00:00Z